Literature DB >> 27495356

Error-related brain activity in youth and young adults before and after treatment for generalized or social anxiety disorder.

Autumn Kujawa1, Anna Weinberg2, Nora Bunford3, Kate D Fitzgerald4, Gregory L Hanna4, Christopher S Monk5, Amy E Kennedy3, Heide Klumpp3, Greg Hajcak6, K Luan Phan7.   

Abstract

Increased error monitoring, as measured by the error-related negativity (ERN), has been shown to persist after treatment for obsessive-compulsive disorder in youth and adults; however, no previous studies have examined the ERN following treatment for related anxiety disorders. We used a flanker task to elicit the ERN in 28 youth and young adults (8-26years old) with primary diagnoses of generalized anxiety disorder (GAD) or social anxiety disorder (SAD) and 35 healthy controls. Patients were assessed before and after treatment with cognitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRI), and healthy controls were assessed at a comparable interval. The ERN increased across assessments in the combined sample. Patients with SAD exhibited an enhanced ERN relative to healthy controls prior to and following treatment, even when analyses were limited to SAD patients who responded to treatment. Patients with GAD did not significantly differ from healthy controls at either assessment. Results provide preliminary evidence that enhanced error monitoring persists following treatment for SAD in youth and young adults, and support conceptualizations of increased error monitoring as a trait-like vulnerability that may contribute to risk for recurrence and impaired functioning later in life. Future work is needed to further evaluate the ERN in GAD across development, including whether an enhanced ERN develops in adulthood or is most apparent when worries focus on internal sources of threat.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety disorders; Cognitive behavior therapy; Endophenotype; Error-related negativity; Pharmacotherapy; Social anxiety disorder

Mesh:

Substances:

Year:  2016        PMID: 27495356      PMCID: PMC4996697          DOI: 10.1016/j.pnpbp.2016.07.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  45 in total

1.  The error-related negativity (ERN) and psychopathology: toward an endophenotype.

Authors:  Doreen M Olvet; Greg Hajcak
Journal:  Clin Psychol Rev       Date:  2008-07-09

2.  Enhanced error-related brain activity in children predicts the onset of anxiety disorders between the ages of 6 and 9.

Authors:  Alexandria Meyer; Greg Hajcak; Dana C Torpey-Newman; Autumn Kujawa; Daniel N Klein
Journal:  J Abnorm Psychol       Date:  2015-02-02

Review 3.  Error-related brain activity in the age of RDoC: A review of the literature.

Authors:  Anna Weinberg; Raoul Dieterich; Anja Riesel
Journal:  Int J Psychophysiol       Date:  2015-03-04       Impact factor: 2.997

4.  Overactive Performance Monitoring as an Endophenotype for Obsessive-Compulsive Disorder: Evidence From a Treatment Study.

Authors:  Anja Riesel; Tanja Endrass; Lea Antonia Auerbach; Norbert Kathmann
Journal:  Am J Psychiatry       Date:  2015-03-17       Impact factor: 18.112

5.  A new method for off-line removal of ocular artifact.

Authors:  G Gratton; M G Coles; E Donchin
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1983-04

6.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

7.  Error-related negativity abnormalities in generalized anxiety disorder and obsessive-compulsive disorder.

Authors:  Zeping Xiao; Jijun Wang; Ming Zhang; Hui Li; Yingying Tang; Yuan Wang; Qing Fan; John A Fromson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-11-24       Impact factor: 5.067

8.  Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers.

Authors:  Ellen R A de Bruijn; Bernard G C Sabbe; Wouter Hulstijn; Gé S F Ruigt; Robbert J Verkes
Journal:  Brain Res       Date:  2006-02-24       Impact factor: 3.252

9.  Defining treatment response and remission in child anxiety: signal detection analysis using the pediatric anxiety rating scale.

Authors:  Nicole E Caporino; Douglas M Brodman; Philip C Kendall; Anne Marie Albano; Joel Sherrill; John Piacentini; Dara Sakolsky; Boris Birmaher; Scott N Compton; Golda Ginsburg; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; John March; John T Walkup
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-11-30       Impact factor: 8.829

10.  The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties.

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-09       Impact factor: 8.829

View more
  22 in total

1.  Error-related Brain Activity as a Treatment Moderator and Index of Symptom Change during Cognitive-Behavioral Therapy or Selective Serotonin Reuptake Inhibitors.

Authors:  Stephanie M Gorka; Katie L Burkhouse; Heide Klumpp; Amy E Kennedy; Kaveh Afshar; Jennifer Francis; Olusola Ajilore; Scott Mariouw; Michelle G Craske; Scott Langenecker; Stewart A Shankman; K Luan Phan
Journal:  Neuropsychopharmacology       Date:  2017-11-28       Impact factor: 7.853

2.  A Neurobehavioral Mechanism Linking Behaviorally Inhibited Temperament and Later Adolescent Social Anxiety.

Authors:  George A Buzzell; Sonya V Troller-Renfree; Tyson V Barker; Lindsay C Bowman; Andrea Chronis-Tuscano; Heather A Henderson; Jerome Kagan; Daniel S Pine; Nathan A Fox
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2017-10-13       Impact factor: 8.829

3.  The error-related negativity (ERN) moderates the association between interpersonal stress and anxiety symptoms six months later.

Authors:  Iulia Banica; Aislinn Sandre; Grant S Shields; George M Slavich; Anna Weinberg
Journal:  Int J Psychophysiol       Date:  2020-04-08       Impact factor: 2.997

4.  A brief, computerized intervention targeting error sensitivity reduces the error-related negativity.

Authors:  Alexandria Meyer; Brittany Gibby; Karl Wissemann; Julia Klawohn; Greg Hajcak; Norman B Schmidt
Journal:  Cogn Affect Behav Neurosci       Date:  2020-02       Impact factor: 3.282

5.  Impact of anxiety symptoms and problematic alcohol use on error-related brain activity.

Authors:  Stephanie M Gorka; K Luan Phan
Journal:  Int J Psychophysiol       Date:  2017-06-09       Impact factor: 2.997

6.  Error-related brain activity in pediatric anxiety disorders remains elevated following individual therapy: a randomized clinical trial.

Authors:  Cecile D Ladouceur; Patricia Z Tan; Vinod Sharma; Lauren M Bylsma; Jennifer S Silk; Greg J Siegle; Erika E Forbes; Dana L McMakin; Ronald E Dahl; Phillip C Kendall; Anthony Mannarino; Neal D Ryan
Journal:  J Child Psychol Psychiatry       Date:  2018-03-30       Impact factor: 8.982

7.  Impact of pubertal timing and depression on error-related brain activity in anxious youth.

Authors:  Amy T Peters; Katie L Burkhouse; Autumn Kujawa; Kaveh Afshar; Kate D Fitzgerald; Christopher S Monk; Greg Hajcak; K Luan Phan
Journal:  Dev Psychobiol       Date:  2018-07-24       Impact factor: 3.038

8.  A Diagnostic Biomarker for Pediatric Generalized Anxiety Disorder Using the Error-Related Negativity.

Authors:  Gregory L Hanna; Yanni Liu; Haley E Rough; Mihir Surapaneni; Barbara S Hanna; Paul D Arnold; William J Gehring
Journal:  Child Psychiatry Hum Dev       Date:  2020-10

9.  The development of the error-related negativity in large sample of adolescent females: Associations with anxiety symptoms.

Authors:  Alexandria Meyer; Corinne Carlton; Sierah Crisler; Alex Kallen
Journal:  Biol Psychol       Date:  2018-09-07       Impact factor: 3.251

10.  Anxiety increases sensitivity to errors and negative feedback over time.

Authors:  Margaret R Tobias; Tiffany A Ito
Journal:  Biol Psychol       Date:  2021-04-15       Impact factor: 3.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.